Maternus-Kliniken Aktiengesellschaft

Informe acción XTRA:MAK

Capitalización de mercado: €36.9m

Maternus-Kliniken Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Maternus-Kliniken's earnings have been declining at an average annual rate of -12.3%, while the Healthcare industry saw earnings growing at 5.8% annually. Revenues have been declining at an average rate of 3.9% per year.

Información clave

-12.3%

Tasa de crecimiento de los beneficios

-12.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare 15.7%
Tasa de crecimiento de los ingresos-3.9%
Rentabilidad financieran/a
Margen neto-6.3%
Última actualización de beneficios30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) 25% Share Price Plunge Could Signal Some Risk

Aug 21
Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) 25% Share Price Plunge Could Signal Some Risk

Maternus-Kliniken Aktiengesellschaft (ETR:MAK) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 05
Maternus-Kliniken Aktiengesellschaft (ETR:MAK) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

A Piece Of The Puzzle Missing From Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) Share Price

Mar 13
A Piece Of The Puzzle Missing From Maternus-Kliniken Aktiengesellschaft's (ETR:MAK) Share Price

Maternus-Kliniken (ETR:MAK) Will Be Hoping To Turn Its Returns On Capital Around

Jul 27
Maternus-Kliniken (ETR:MAK) Will Be Hoping To Turn Its Returns On Capital Around

The Returns On Capital At Maternus-Kliniken (ETR:MAK) Don't Inspire Confidence

Feb 22
The Returns On Capital At Maternus-Kliniken (ETR:MAK) Don't Inspire Confidence

Some Investors May Be Worried About Maternus-Kliniken's (ETR:MAK) Returns On Capital

Jul 27
Some Investors May Be Worried About Maternus-Kliniken's (ETR:MAK) Returns On Capital

Estimating The Fair Value Of Maternus-Kliniken Aktiengesellschaft (ETR:MAK)

Jun 10
Estimating The Fair Value Of Maternus-Kliniken Aktiengesellschaft (ETR:MAK)

Desglose de ingresos y gastos

Cómo gana y gasta dinero Maternus-Kliniken. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

XTRA:MAK Ingresos, gastos y beneficios (EUR Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Jun 24109-700
31 Mar 24106-1100
31 Dec 23102-1400
30 Sep 23102-1700
30 Jun 23102-1900
31 Mar 23105-1600
31 Dec 22107-1400
30 Sep 22108-1000
30 Jun 22110-600
31 Mar 22111-400
31 Dec 21111-300
30 Sep 21114-500
30 Jun 21116-700
31 Mar 21115-800
31 Dec 20114-1000
30 Sep 20116-1010
30 Jun 20117-1020
31 Mar 20121-1030
31 Dec 19124-1050
30 Sep 19125-760
30 Jun 19125-580
31 Mar 19125-3110
31 Dec 18124-2130
30 Sep 18125-2170
30 Jun 18126-2210
31 Mar 18126-2170
31 Dec 17127-1140
30 Sep 171270140
30 Jun 171262140
31 Mar 171251140
31 Dec 161241140
30 Sep 161244210
30 Jun 161242140
31 Mar 161242140
31 Dec 151232140
30 Sep 1512328140
30 Jun 1512428140
31 Mar 1512328140
31 Dec 1412227140
30 Sep 14120-9150
30 Jun 14118-10150
31 Mar 14115-11150
31 Dec 13114-13150

Ingresos de calidad: MAK is currently unprofitable.

Margen de beneficios creciente: MAK is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: MAK is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Acelerando crecimiento: Unable to compare MAK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: MAK is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (30.9%).


Rentabilidad financiera

Alta ROE: MAK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado